Laurus Labs posts strong Q2 and H1 FY26 results
LAURUSLABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.7 pts less than Nifty Midcap 150 and 1.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Unaudited Q2 and H1 FY26 results showed revenue growth of 35% and 33%, respectively. Q2 revenue was Rs 1,653 crore, EBITDA was Rs 429 crore and net profit was Rs 195 crore. H1 revenue was Rs 3,223 crore, EBITDA Rs 818 crore and net profit Rs 358 crore. H1 EBITDA margin expanded 10.8 percentage points to 25.4%. The company declared an interim dividend of Rs 0.80 per share and continues investing in capacity.
Strong growth, wider margins and a dividend support shareholders, though results are unaudited and future performance depends on execution and demand.